YPI 011
/ KT&G Corp
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 24, 2024
A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=88 | Completed | Sponsor: Yungjin Pharm. Co., Ltd. | Recruiting ➔ Completed
Trial completion • Gastroenterology • Gastroesophageal Reflux Disease
February 24, 2023
Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole.
(PubMed, Drug Des Devel Ther)
- "The PK-PD relationship of PPI is well known, and the faster absorption of rabeprazole resulted in a more rapid mode of action in acid suppression. The fixed dose combination of rabeprazole with NaHCO showed a faster absorption and consequently, a more rapid gastric acid suppression with a similar systemic exposure of rabeprazole at steady state compared to the conventional enteric-coated rabeprazole."
Journal • Gastroenterology • Gastroesophageal Reflux Disease
February 02, 2021
A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=88; Recruiting; Sponsor: Yungjin Pharm. Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Gastroenterology • Gastroesophageal Reflux Disease
January 11, 2021
A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=88; Not yet recruiting; Sponsor: Yungjin Pharm. Co., Ltd.
Clinical • New P1 trial • Gastroenterology • Gastroesophageal Reflux Disease
1 to 4
Of
4
Go to page
1